Why the study?
Cardiovascular diseases remain the leading cause of death worldwide, highlighting the need for effective, multi-functional treatment alternatives.
Do PPAR alpha and gamma agonists provide cardioprotective effects and reduce myocardial damage?
Do PPAR alpha and gamma agonists provide cardioprotective effects and reduce myocardial damage?
This review highlights the potential of PPAR alpha and gamma agonists to provide cardioprotection through pleiotropic molecular mechanisms that prevent myocardial damage.
Answers are grounded in this paper and cite their sources.
May support PPAR agonist evaluation in myocardial injury; leaves open confirmation in randomized trials.
Cardiovascular diseases remain the leading cause of death in the world, and that is why finding an effective and multi-functional treatment alternative to combat these diseases has become more important. Fibrates and thiazolidinediones, peroxisome proliferator-activated receptors alpha and gamma are the pharmacological therapies used to treat dyslipidemia and type 2 diabetes, respectively. New mechanisms of action of these drugs have been found, demonstrating their pleiotropic effects, which contribute to preserving the heart by reducing or even preventing myocardial damage. Here, we review the mechanisms underlying the cardioprotective effects of PPAR agonists and regulating morphological and physiological heart alterations (metabolic flexibility, mitochondrial damage, apoptosis, structural remodeling, and inflammation). Moreover, clinical evidence regarding the cardioprotective effect of PPAR agonists is also addressed.
No takes yet. Share an insight, caveat, or question.
Rubio-Ruiz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: